XENE Research and Charts

XENE - Xenon Pharmaceuticals Inc (Healthcare: Biotechnology)

Projected Earnings Date: 2026-02-02 (Delayed quote data 2026-02-10)

Last 42.63	Change ⇑ +0.20 (+0.47%)	Volume 881,587
	Open 43.00	High 43.67	Low 42.13

8EMA (Daily) 41.81	40EMA (Daily) 41.99	50EMA (Daily) 41.94	STO (Daily) 49.138	MACD Hist (Daily) 0.192
8EMA (Weekly) 42.058	40EMA (Weekly) 39.83	50EMA (Weekly) 39.46	STO (Weekly) 43.524	MACD Hist (Weekly) -0.510


Company Profile
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders, including the rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901 and XEN496 for Epilepsy, XEN007 for Orphan neurological, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out through Canada.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.